QXAS yields 25.02% · PFE yields 6.13%● Live data
📍 QXAS pulled ahead of the other in Year 1
Combined, QXAS + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of QXAS + PFE for your $10,000?
QXAS seeks 2x daily exposure to the largest crypto assets, excluding Bitcoin (BTC), stablecoins, and memecoins. It does not hold crypto directly, but gains exposure via swaps, options, futures contracts, or ETPs, targeting up to 10 crypto assets traded in US exchanges. The fund uses options contracts for leveraged exposure, allowing dynamic adjustments based on market conditions, liquidity, or pricing. The fund buys standardized, cash-settled futures to manage contango and backwardation and invests in ETPs for long exposure. The fund holds cash and cash-like instruments as collateral and may enter reverse repurchase agreements. Up to 25% of assets may be invested through a wholly owned Cayman Islands subsidiary. The market cap-weighted portfolio is reviewed and rebalanced at least monthly, capping each asset at 50%. The actively managed fund has full discretion to adjust at any time. Daily leverage resets may cause long-term returns to differ from the underlying assets.
Full QXAS Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.